^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Mesothelioma

Related cancers:
16h
Dose Individualization of Pemetrexed - IMPROVE-I (clinicaltrials.gov)
P4, N=6, Completed, Radboud University Medical Center | Phase classification: P2 --> P4
Phase classification
|
pemetrexed • leucovorin calcium
17h
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=200, Recruiting, BeiGene | Active, not recruiting --> Recruiting | N=37 --> 200 | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
Tevimbra (tislelizumab-jsgr) • BGB-30813
21h
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma. (PubMed, Front Immunol)
Patients with pleural mesothelioma treated with nivolumab and ipilimumab with or without UV1 vaccine in the NIPU study were included. Elevated levels of certain cytokines, both before and after onset of treatment, correlate with specific irAEs in PM patients receiving ICIs. These cytokines may be used as biomarkers to predict and detect irAES.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL11 (C-C Motif Chemokine Ligand 11) • IL4 (Interleukin 4) • IL16 (Interleukin 16)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • UV1
23h
Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells. (PubMed, Int J Cancer)
We revealed that the HIF1A inhibitors echinomycin (EC) and YC-1 upregulated CXCL10/11 genes induced by IFN-γ in tumor cells in vitro...Combination therapy enhanced tumor infiltration of CD8 T cells and suppressed tumor angiogenesis. The present study suggests that HIF1A signaling in tumor cells dominates ICI resistance via the downregulation of tumor-derived CXCL10/11.
Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
HIF1A expression • CXCL10 expression
|
echinomycin
1d
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma. (PubMed, J Clin Med)
ILK showed no prognostic value. Further studies with larger cohorts are needed to identify prognostic and predictive biomarkers facilitating optimized individual treatment decision in this rare type of cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BAP1 (BRCA1 Associated Protein 1) • ILK (Integrin Linked Kinase)
|
PD-L1 expression
6d
Radiomics for differentiation of somatic BAP1 mutation on CT scans of patients with pleural mesothelioma. (PubMed, J Med Imaging (Bellingham))
This proof-of-concept work demonstrated the potential of radiomics to differentiate among BAP1+/- in patients with PM. Future work will extend these methods to the assessment of germline BAP1 mutation status through image analysis for improved patient prognostication.
Journal • BRCA Biomarker
|
BAP1 (BRCA1 Associated Protein 1)
|
BAP1 mutation
6d
Establishment and bioinformatics analysis of a four-miRNA prognostic signature for pleural mesothelioma. (PubMed, J Cancer)
Moreover, all four miRNAs (hsa-miR-181a-2-3p, hsa-miR-491-5P, hsa-miR-503-5p, and hsa-miR-3934-5p) were found to be differentially expressed in PM cell lines as compared with normal cell line, GO and KEGG analysis revealed that target genes of miRNAs in prognostic model were involved in multiple tumor-associated signaling pathways and functions in PM, core miRNA targets also correlated with immune cell infiltration, indicating their potential role in PM initiation and progression. A robust four-miRNA prognostic signature with great performances in prediction of the OS for PM patients was developed in our study, providing new avenues for the prognostic predication of PM.
Journal
|
MIR503 (MicroRNA 503) • MIR181A1 (MicroRNA 181a-1)
6d
Enrollment change • Metastases
|
MTAP (Methylthioadenosine Phosphorylase)
|
MTAP deletion
|
Keytruda (pembrolizumab) • TNG462
6d
Pathological characterization of lung fibrosis in Sprague-Dawley rats treated with fluoro-edenite fibres by intrapleural injection. (PubMed, J Occup Med Toxicol)
This study confirmed that FE exposure promotes the onset of fibrotic lesions at pleural level, as fibrous plaques or nodules and fibrosis, through a mechanism similar to other form of asbestos. These results combined with epidemiological study reported in Biancavilla residents, corroborate the need to promote health and epidemiological surveillance plans of respiratory diseases in population living in FE contaminated sites.
Preclinical • Journal
|
VIM (Vimentin)
|
VIM expression
7d
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas (clinicaltrials.gov)
P1, N=321, Recruiting, Inhibrx Biosciences, Inc | N=240 --> 321 | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
cisplatin • carboplatin • 5-fluorouracil • temozolomide • pemetrexed • irinotecan • ozekibart (INBRX-109)
7d
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Recruiting --> Active, not recruiting | N=102 --> 52
Enrollment closed • Enrollment change
|
Photofrin (porfimer sodium)
9d
KEYNOTE-483: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2/3, N=520, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Apr 2023 --> Oct 2024
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • cisplatin • pemetrexed
15d
Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases. (PubMed, Clin Epigenetics)
DNA methylation analyses provide a robust method for distinguishing PM from healthy pleural tissues, and specific methylation patterns exist within PM subtypes. These methylation differences underscore their importance in understanding disease progression and may serve as viable biomarkers or therapeutic targets. Moreover, differential methylation patterns between PM and other lung cancers highlights its diagnostic potential. These findings necessitate further translational studies to explore their clinical applications.
Journal • Epigenetic controller
|
MIR21 (MicroRNA 21)
15d
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. (PubMed, JTO Clin Res Rep)
Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on the basis of MAPS2 results. The highest-grade TRAE was 1 to 2 in 58% of these patients and 3 or higher in 42% Treatment discontinuation due to a TRAE occurred in 22% of patients. In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar.
Journal • Real-world evidence • PD(L)-1 Biomarker • Real-world
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • pemetrexed
16d
BICEP: Exercise to Boost Immunity in Advanced Cancer (clinicaltrials.gov)
P=N/A, N=30, Not yet recruiting, Sheffield Teaching Hospitals NHS Foundation Trust | Trial completion date: Mar 2026 --> Mar 2027 | Initiation date: Sep 2024 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Mar 2027
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
20d
A case of ovarian mesothelioma with VHL mutation diagnosed by immunohistochemistry and literature review. (PubMed, Front Oncol)
Through the literature search, we reviewed primary ovarian mesothelioma, focusing on its differential diagnosis and molecular genetics. The purpose of this paper is to deepen the flexible selection and application of immunohistochemical markers in mesothelioma, so as to reduce missed diagnosis and misdiagnosis.
Review • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
20d
The prognostic value of BAP1 protein loss in patients with malignant mesothelioma (PubMed, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi)
Multivariate model results showed that positive expression of BAP1 protein (HR=3.75, 95%CI: 2.23-6.30, P<0.001) and age ≥57 years (HR=1.66, 95% CI: 1.01-2.72, P=0.049) were risk factors for survival in patients with MM. Loss of BAP1 protein expression may be an independent prognostic factor in patients with MM, which is associated with longer survival.
Journal • BRCA Biomarker
|
BAP1 (BRCA1 Associated Protein 1)
22d
Unveiling a rare haemorrhagic malignant pleural effusion: The role of medical thoracoscopy in diagnosing primary pleural angiosarcoma. (PubMed, Respirol Case Rep)
Tragically, the patient developed a hospital-acquired infection and passed away before any definitive treatment for the angiosarcoma could be initiated. This case underscores the diagnostic complexities of PPA and highlights the utility of MT in identifying this rare malignancy.
Journal • Pleural effusion
|
VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
24d
A pan-cancer analysis of the oncogenic function of HMGB1 in human tumors. (PubMed, Biochem Biophys Rep)
Additionally, we discovered that the frequency of HMGB1 mutations ranked among the top 20 mutated genes in the 95 patients' data, indicating that HMGB1 plays an important role in the development and prognosis of various solid tumors. This pan-cancer study of HMGB1 underscores its potential as a signature marker and target for the management of various tumor types.
Journal • BRCA Biomarker • Pan tumor
|
BRCA (Breast cancer early onset) • HMGB1 (High Mobility Group Box 1)
|
BRCA mutation
24d
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs (clinicaltrials.gov)
P=N/A, N=0, Withdrawn, Travera Inc | N=630 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
26d
New P1 trial • Metastases
26d
Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. (PubMed, JCI Insight)
With a gradual reduction of CAR affinity toward the micromolar KD, the expansion of CAR T cells became more restricted to tumors. Our preclinical studies demonstrated that high-affinity MSLN CARs were associated with fatal on-target, off-tumor toxicity and that affinity-tuned CARs rendered T cells more selective for MSLN-high tumors.
Journal • CAR T-Cell Therapy
|
MSLN (Mesothelin)
30d
Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov)
P1, N=10, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2024 | Trial primary completion date: Jul 2025 --> Nov 2024
Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
WT1 (WT1 Transcription Factor)
|
Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
1m
Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study. (PubMed, Genome Med)
Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma.
P1 data • Journal • CAR T-Cell Therapy • IO biomarker
|
MSLN (Mesothelin) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
|
MSLN expression • MSLN positive
1m
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (clinicaltrials.gov)
P1, N=67, Terminated, Ikena Oncology | N=198 --> 67 | Trial completion date: Jun 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Aug 2024; Sponsor strategic reasons
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CAMTA1 (Calmodulin Binding Transcription Activator 1) • TAFAZZIN (Tafazzin)
|
TFE3 fusion
|
Tagrisso (osimertinib) • IK-930
1m
NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma. (PubMed, Lung Cancer)
NOTCH2 and PTP4A3 alterations are associated with clinical outcomes in pemetrexed-treated PM patients. The inhibition of NOTCH pathway may be exploited to eradicate CSCs and improve patients' survival.
Journal
|
NOTCH1 (Notch 1) • NOTCH2 (Notch 2) • PTP4A3 (Protein Tyrosine Phosphatase 4A3)
|
pemetrexed
1m
Synchronous Pleural and Peritoneal Mesothelioma in a Free-Ranging Capuchin Monkey (Sapajus libidinosus). (PubMed, J Med Primatol)
A free-ranging capuchin monkey developed a synchronous biphasic pleural and peritoneal mesothelioma, a rare form of this tumor. Exophytic nodules were dispersed over the serosal surfaces, showing marked microscopical malignant features composed of both epithelioid and spindeloid neoplastic cells immunopositive for Pan-Cytokeratin, Cytokeratin 5/6, Vimentin, WT-1, and D2-40.
Preclinical • Journal
|
WT1 (WT1 Transcription Factor) • VIM (Vimentin) • KRT5 (Keratin 5)
1m
Morphological analysis and cytotoxicity of acrylamide on SPC212 human mesothelioma cells: Do low doses induce proliferation, while high doses cause toxicity? (PubMed, J Cell Mol Med)
This is the acrylamide-associated first study conducted on SPC212 mesothelioma cells encompassing advanced morphological analysis. We believe this study to be an incentive for future studies.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen)
1m
miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology? (PubMed, Future Cardiol)
MiRNAs are crucial for cardiac development through the expression of cardiac transcription factors (miR-335-5p), hinder the cell cycle by modulating the activity of transcription factors (miR-126-3p, miR-320a), modulate the production of inflammatory factors such as interleukins (miR-217), and interfere with cell proliferation or apoptosis (miR-218, miR-634 and miR-122). Current and future research on miRNAs is essential, as a deep understanding could lead to a revolution in the field of diagnostics and prevention of neoplastic diseases.
Review • Journal
|
MIR126 (MicroRNA 126) • MIR320A (MicroRNA 320a) • MIR335 (MicroRNA 335) • MIR122 (MicroRNA 122) • MIR217 (MicroRNA 217) • MIR218 (MicroRNA 218)
1m
Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions. (PubMed, BJC Rep)
Our findings demonstrate the utility of the interactome in uncovering biological associations and in generating clinically translatable results.
Journal
|
IL6 (Interleukin 6)
1m
Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall. (PubMed, Onco Targets Ther)
The patient was treated with a chemotherapy regimen of pemetrexed and carboplatin. Mesothelioma with predominantly intrapulmonary growth is extremely rare and poses a diagnostic pitfall. For this entity, subtle morphological features, selection of immunohistochemical markers, and electron microscopy are of great significance for definite diagnosis.
Journal
|
WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
|
TTF1 negative
|
carboplatin • pemetrexed
1m
Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib. (PubMed, J Int Med Res)
In this particular case, treatment with crizotinib demonstrated some initial efficacy, which suggests that this might be a promising strategy for patients with advanced MPM with an ALK gene mutation. This required further research and evaluation in the future.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement • ALK fusion • ALK mutation
|
Xalkori (crizotinib)
1m
TNG908-C101: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors (clinicaltrials.gov)
P1/2, N=192, Active, not recruiting, Tango Therapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
MTAP (Methylthioadenosine Phosphorylase)
|
MTAP deletion
|
TNG908
1m
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (clinicaltrials.gov)
P2, N=40, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
1m
INFINITE: Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (clinicaltrials.gov)
P3, N=53, Active, not recruiting, Ferring Ventures Limited | Trial completion date: Nov 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Mar 2024
Trial completion date • Trial primary completion date • Combination therapy
|
MSLN (Mesothelin) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1)
|
gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral
1m
Ascites as a Rare Manifestation of Malignant Peritoneal Mesothelioma: A Case Report. (PubMed, Cureus)
It also revealed tumor cells positive for p53, calretinin, WT1, and podoplanin (D2-40). This case highlights the importance of considering MPM in the differential diagnosis for patients with ascites and possible asbestos exposure, particularly with respect to occupational hazards, as it is a rare manifestation of the disease.
Journal
|
WT1 (WT1 Transcription Factor)
1m
Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis. (PubMed, BMC Cancer)
In this meta-analysis we found that anti-PD1/PD-L1 treatment could be useful in pretreated asMM as they had at least comparable or greater mPFS, mOS, ORR, and DCR than other second-line agents currently being used.
Retrospective data • Review • Journal • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Bavencio (avelumab)
1m
Stereotactic Magnetic Resonance Guided Radiation Therapy (clinicaltrials.gov)
P=N/A, N=397, Recruiting, Dana-Farber Cancer Institute | Suspended --> Recruiting
Enrollment open
1m
PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov)
P2, N=58, Active, not recruiting, The Netherlands Cancer Institute | Trial completion date: Mar 2025 --> Mar 2026
Trial completion date
|
TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
1m
Pancancer analysis of the interactions between CTNNB1 and infiltrating immune cell populations. (PubMed, Medicine (Baltimore))
Additionally, pathway enrichment suggested that NUMB is involved in the Wnt pathway. This study highlights the predictive role of CTNNB1 across cancers, suggesting that CTNNB1 might serve as a potential biomarker for the diagnosis and prognosis evaluation of various malignant tumors.
Journal • Pan tumor • Immune cell
|
CD8 (cluster of differentiation 8) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RHOA (Ras homolog family member A)
|
CTNNB1 mutation • CTNNB1 expression
2ms
Preclinical • Journal • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
2ms
Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review). (PubMed, Oncol Lett)
The present review discusses the value and limitations of each type of biomarker, and potential solutions to address the limitations are proposed. The aim of the present review is to provide a background for future studies on ICB-based therapy for MPeM.
Review • Journal • Checkpoint inhibition • BRCA Biomarker • Checkpoint block
|
BAP1 (BRCA1 Associated Protein 1)